No quarterly revenue total was found in OS THERAPIES INCORPORATED's SEC filings.
Os Therapies Incorporated (OSTX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-8.63M
-90.3% vs year-ago quarter
Operating cash flow
$-5.53M
-134.4% vs year-ago quarter
Free cash flow
$-3.73M
+27.9% vs prior quarter
EPS
$-0.20
-5.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
46.13M
+44.6% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OSTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1795091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$8.6M | -$10.2M | -$12.0M | -$6.9M | -$4.8M |
| Net income | -$8.6M | -$10.4M | -$13.5M | -$6.9M | -$4.5M |
| Diluted EPS | -$0.20 | -$0.27 | -$0.39 | -$0.21 | -$0.19 |
| Operating cash flow | -$5.5M | -$4.6M | -$3.7M | -$4.7M | -$2.4M |
| Free cash flow | — | — | -$3.7M | -$5.2M | -$2.7M |
| Total assets | $9.9M | $7.3M | $6.8M | $9.0M | $10.3M |
| Total liabilities | $20.7M | $17.1M | $11.9M | $4.2M | $3.6M |
| Stockholders' equity | -$11.9M | -$10.8M | -$6.1M | $3.6M | $4.9M |
| Cash and investments | $205,035 | $917,552 | $269,830 | — | $2.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
Oct 5, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 243 Os Therapies Incorporated SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.